Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others), By Treatment (Medication, Surgery, Others), By Route of Administration (Oral, Parenteral, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Overview

Global Atherosclerosis Drugs Market was valued at USD 18.85 Billion in 2024 and is expected to reach USD 22.84 Billion by 2030 with a CAGR of 3.21% during the forecast period. Atherosclerosis, a condition characterized by the narrowing and hardening of arteries due to the accumulation of fatty deposits, remains a major global health concern. It is a leading cause of heart disease, stroke, and other cardiovascular complications, contributing to millions of deaths annually. The Global Atherosclerosis Drugs Market, driven by the increasing prevalence of this condition, has witnessed significant growth in recent years. Atherosclerosis is increasingly prevalent worldwide, mainly due to unhealthy lifestyles, including poor diet, lack of physical activity, and smoking. This has created a substantial patient pool in need of treatment and management. The aging global population is at a higher risk of atherosclerosis. As the elderly demographic grows, so does the demand for atherosclerosis drugs. Advancements in medical technology and diagnostics have enabled early detection of atherosclerosis, promoting timely intervention and medication. Public awareness campaigns and educational efforts have made people more conscious of their cardiovascular health, leading to more individuals seeking treatment. The Global Atherosclerosis Drugs Market presents both opportunities and challenges. As the burden of atherosclerosis continues to rise, innovation and research are crucial in developing effective treatments. Personalized medicine and targeted therapies hold promise in improving patient outcomes. However, addressing issues related to drug pricing, adherence, and emerging competition will be essential to ensure that atherosclerosis drugs remain accessible to those in need. Ultimately, the collaboration of pharmaceutical companies, healthcare providers, and policymakers is essential in the fight against atherosclerosis and its devastating consequences on global health.

Key Market Drivers

Rising Prevalence of Atherosclerosis is Driving the Global Atherosclerosis Drugs Market

Atherosclerosis, a condition characterized by the build-up of plaque in arteries, is becoming increasingly prevalent worldwide. This arterial disease poses significant health risks, including heart attacks and strokes, making it a global healthcare concern. Consequently, the global atherosclerosis drugs market is on the rise, driven by the growing need for effective treatments. Modern lifestyles often involve long hours of sitting, reduced physical activity, and poor dietary choices. These factors contribute to obesity, hypertension, and elevated cholesterol levels, all of which increase the risk of atherosclerosis.

Diets high in saturated fats, trans fats, and processed foods are common in many parts of the world. These diets not only contribute to obesity but also raise the levels of LDL (low-density lipoprotein) cholesterol, a major risk factor for atherosclerosis. Atherosclerosis is more prevalent among older individuals. As the global population ages, the incidence of atherosclerosis is expected to increase, placing additional strain on healthcare systems. Tobacco use remains a significant risk factor for atherosclerosis. Despite public health campaigns to reduce smoking rates, many individuals continue to smoke, further exacerbating the problem. Diabetes is associated with a higher risk of atherosclerosis due to elevated blood sugar levels and other metabolic changes. The rising prevalence of diabetes worldwide contributes to the increasing incidence of atherosclerosis. Scientists have uncovered cancer-like features in atherosclerosis, revealing potential for new treatment strategies. Research supported by the National Institutes of Health (NIH) suggests that the smooth muscle cells lining the arteries in individuals with atherosclerosis can transform into new cell types, adopting characteristics similar to cancer cells, which worsen the condition. Atherosclerosis causes arterial narrowing, increasing the risk of coronary artery disease, stroke, peripheral artery disease, and kidney disorders. These findings could lead to the development of new therapies that use anti-cancer drugs to target the tumor-like processes responsible for plaque buildup in the arteries, which is a major cause of cardiovascular disease.

The rising prevalence of atherosclerosis has led to a growing demand for effective treatments, which, in turn, is driving the global atherosclerosis drugs market. Several factors are contributing to the market's expansion. Pharmaceutical companies are investing heavily in research and development to create innovative drugs for atherosclerosis treatment. These efforts aim to develop more effective medications with fewer side effects. Public awareness campaigns and educational initiatives are helping individuals recognize the risk factors and symptoms of atherosclerosis, leading to earlier diagnosis and treatment. Lifestyle modifications, including diet and exercise, play a crucial role in managing atherosclerosis. This has spurred the development of complementary products and services, such as dietary supplements and fitness programs, which are also contributing to the market's growth. Technological advancements in diagnostic imaging techniques, such as CT scans and angiography, allow for earlier and more accurate detection of atherosclerosis, facilitating timely intervention and treatment. Collaboration between pharmaceutical companies, healthcare providers, and research institutions is fostering innovation and the development of comprehensive treatment approaches.

Increasing Geriatric Population is Driving the Global Atherosclerosis Drugs Market

The global healthcare landscape is witnessing a significant transformation as the world's population ages. One of the key health concerns associated with aging is atherosclerosis, a condition characterized by the buildup of plaque in the arteries, leading to various cardiovascular diseases. As the aging population continues to grow, the demand for atherosclerosis drugs is on the rise, propelling the global atherosclerosis drugs market to new heights. The global population is aging at an unprecedented rate. According to the World Health Organization (WHO), by 2050, it is projected that 80% of the global elderly population will reside in low- and middle-income countries. The rate of population aging is accelerating compared to previous decades. In 2020, the number of individuals aged 60 and above surpassed the number of children under 5 years of age. From 2015 to 2050, the percentage of the global population aged over 60 is expected to nearly double, increasing from 12% to 22%. As individuals age, their risk of developing atherosclerosis and related cardiovascular conditions significantly increases. This demographic shift is a primary driver behind the growing demand for atherosclerosis drugs.

With atherosclerosis as a key contributor to heart attacks, strokes, and other cardiovascular diseases, the rising aging population directly correlates with an increased incidence of these conditions. This necessitates a greater need for effective atherosclerosis drugs. Advances in healthcare, nutrition, and lifestyle have contributed to longer life expectancy. While this is undoubtedly a positive development, it also means that individuals are exposed to the risk of atherosclerosis and its complications for a more extended period, further fueling the demand for treatment options. Aging is associated with various risk factors for atherosclerosis, such as hypertension, diabetes, and high cholesterol levels. As the population ages, the prevalence of these risk factors rises, underscoring the need for pharmacological interventions.

Pharmaceutical companies are exploring novel therapeutic approaches to manage atherosclerosis. These include targeted therapies that aim to reduce plaque buildup and inflammation within arterial walls. Advancements in genomics and personalized medicine are enabling healthcare providers to tailor atherosclerosis treatments to individual patients, optimizing efficacy and minimizing side effects. Researchers are investigating combinations of drugs with complementary mechanisms of action to enhance treatment outcomes and reduce the risk of disease progression. Pharmaceutical companies are also investing in educational initiatives to raise awareness about atherosclerosis risk factors and prevention strategies, emphasizing the importance of a healthy lifestyle.

Download Free Sample Report

Key Market Challenges

Increasing Competition

The atherosclerosis drugs market is highly competitive, with a mix of established global pharmaceutical companies and emerging players all striving for a piece of the market share. Large pharmaceutical companies like Pfizer, AstraZeneca, and Merck have long dominated the space, driven by blockbuster drugs such as Lipitor (atorvastatin) and Crestor (rosuvastatin), which have provided these companies with significant revenue streams for years. However, newer entrants are also competing for attention with innovative therapies and specialized drug formulations that target different aspects of atherosclerosis treatment. For example, companies are focusing on niche segments, such as those targeting LDL cholesterol reduction or inflammation, in an attempt to capture demand from patients who have not been adequately treated by existing options. The growing presence of biosimilars and generics has also intensified competition, as these lower-cost alternatives to branded drugs are becoming more prevalent. Smaller companies or startups attempting to enter the market may face substantial hurdles, such as the complexity of navigating strict regulatory environments, securing approval for new drugs, and gathering enough financial resources for large-scale clinical trials. These challenges are amplified by the entrenched presence of market leaders, which can make it difficult for newcomers to differentiate their products and capture market share. As competition increases, companies must continually innovate, either through the development of new drug formulations, partnerships, or strategic acquisitions, to remain competitive.

Price Pressures and Healthcare Costs

A significant challenge in the atherosclerosis drugs market is the rising cost of healthcare, which is impacting both pharmaceutical companies and patients. While novel therapies have shown substantial benefits, they often come with a hefty price tag due to the research and development costs required to bring these drugs to market. Additionally, as the market for cardiovascular drugs expands with new, advanced treatments, the pricing for these medications has escalated, which further compounds the issue. Government healthcare systems and private insurance companies are increasingly scrutinizing the prices of high-cost drugs, placing more pressure on manufacturers to reduce the price of their products. This trend is especially prevalent in developed markets such as the United States and Europe, where healthcare systems are facing increased financial strain due to aging populations and rising demand for medical care. Pharmaceutical companies are under pressure to lower drug prices to gain reimbursement approvals from insurers, which increasingly dictate access to treatments. For atherosclerosis drugs, in particular, the challenge lies in balancing the high cost of new medications with the demand for affordable treatments that patients can access. Manufacturers need to demonstrate both clinical efficacy and cost-effectiveness to secure their place in the market. Additionally, with the growing prevalence of generics and biosimilars, cost-conscious patients and healthcare providers may opt for more affordable alternatives, further driving down prices and putting additional financial pressure on brand-name drug manufacturers. As the push for affordable healthcare intensifies, pharmaceutical companies must innovate not only in terms of drug efficacy but also in finding ways to keep costs down while maintaining profitability.

Key Market Trends

Technological Advancements

Atherosclerosis, a chronic condition characterized by the buildup of plaque in arteries, has long been a significant health concern worldwide. It is a leading cause of heart disease, strokes, and other cardiovascular diseases, contributing to millions of deaths annually. However, with the relentless march of technological advancements in the healthcare sector, there is newfound hope for combating atherosclerosis. These innovations are revolutionizing the development, diagnosis, and treatment of atherosclerosis, which in turn is driving the growth of the global atherosclerosis drugs market. In August 2022, AstraZeneca and Merck, referred to as MSD in regions outside the United States and Canada, made an announcement that the European Commission (EC) had granted approval for LYNPARZA, either as a standalone treatment or in conjunction with endocrine therapy. This approval applies to the adjuvant treatment of adult patients who have germline BRCA1/2 mutations (gBRCAm) and are diagnosed with HER2-negative high-risk early breast cancer, provided they have undergone neoadjuvant or adjuvant chemotherapy previously.

Modern imaging technologies like CT angiography, magnetic resonance imaging (MRI), and intravascular ultrasound (IVUS) provide high-resolution images of blood vessels, allowing healthcare professionals to visualize plaque buildup and assess its severity accurately. Blood tests now incorporate biomarkers that can detect specific molecules associated with atherosclerosis, such as high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2). These tests aid in early detection and risk assessment. AI and machine learning algorithms are being employed to analyze medical imaging and patient data, helping to identify patterns and predict atherosclerosis development. This technology enhances the efficiency and accuracy of diagnosis.

Advances In Pharmacogenomics And Personalized Medicine

Advances in pharmacogenomics and personalized medicine are enabling the development of drugs that target specific genetic markers associated with atherosclerosis, improving treatment efficacy and minimizing side effects. Nanoparticles are being utilized to deliver drugs directly to arterial plaques, enhancing drug effectiveness while minimizing systemic side effects. Technological innovations have led to the development of drug-eluting stents, which are coated with medications that prevent restenosis (re-narrowing of arteries) after angioplasty and stent placement. Cutting-edge gene-editing techniques like CRISPR-Cas9 hold the potential to address the genetic factors contributing to atherosclerosis, opening up new avenues for treatment development. In September 2022, Novo Nordisk established a fresh strategic partnership with Microsoft aimed at expediting pharmaceutical research and development by leveraging big data and artificial intelligence (AI). The collaborative team intends to utilize AI to create predictive models for assessing an individual's susceptibility to atherosclerosis or the formation of arterial plaque. Additionally, researchers will explore novel targets and markers associated with atherosclerosis.

Telehealth platforms and wearable devices enable healthcare providers to remotely monitor patients with atherosclerosis, allowing for early intervention and reducing hospitalization rates. Mobile applications and wearable devices can track vital signs, physical activity, and dietary habits, empowering patients to take a proactive role in managing their condition. The analysis of large datasets is providing valuable insights into atherosclerosis epidemiology, treatment outcomes, and patient responses, helping refine treatment approaches.

Segmental Insights

Route of Administration Insights

Based on the category of Route of Administration, Oral emerged as the dominant player in the global market for Atherosclerosis Drugs. The oral route of administration, where medications are taken by mouth in the form of tablets, capsules, or liquids, has emerged as the preferred choice for atherosclerosis drugs for several compelling reasons. One of the primary advantages of the oral route is its simplicity and ease of use. Patients can take medications at home without the need for medical supervision or invasive procedures. This convenience often leads to better adherence to treatment regimens, improving overall patient outcomes. Patients are generally more receptive to oral medications because they are familiar with this method. This ease of acceptance can lead to increased patient compliance, a critical factor in managing chronic conditions like atherosclerosis. Oral medications can be formulated in various ways, including extended-release formulations that provide continuous drug delivery over time. This allows for tailored treatment plans to meet individual patient needs. Oral medications tend to be more cost-effective than other routes of administration, such as intravenous or transdermal options. This affordability can make treatment more accessible to a broader range of patients. Pharmaceutical companies often focus their research and development efforts on oral formulations due to their wide market appeal. This results in a more extensive selection of oral atherosclerosis drugs and innovative formulations. The oral route typically presents fewer side effects compared to other administration methods, such as injections. This can enhance the overall patient experience and treatment compliance.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the global Atherosclerosis Drugs market, holding the largest market share in terms of value. One of the primary reasons behind North America's dominance in the global atherosclerosis drugs market is the high incidence of atherosclerosis in the region. Factors such as a sedentary lifestyle, unhealthy dietary habits, and a growing aging population have contributed to a significant prevalence of atherosclerotic diseases, including coronary artery disease and peripheral artery disease. This high disease burden has led to a substantial demand for atherosclerosis drugs. North America boasts a well-developed and advanced healthcare infrastructure. The region is home to some of the world's leading pharmaceutical companies, research institutions, and healthcare providers. This infrastructure enables the efficient development, testing, and distribution of atherosclerosis drugs, fostering innovation and driving market growth. North America invests heavily in research and development (R&D) activities related to atherosclerosis drugs. Pharmaceutical companies in the United States and Canada dedicate substantial resources to discover and develop novel therapies for atherosclerosis. These investments not only drive product innovation but also enhance the competitiveness of the North American market in the global arena.

Recent Developments

• In June 2024, Researchers at the University of Bristol have discovered a novel disease-driving mechanism that could potentially be targeted to treat the development of atherosclerotic plaques. The project, which aims to develop a new therapeutic known as IMSET, is led by Professor Jason Johnson, a specialist in Cardiovascular Pathology at the Bristol Medical School: Translational Health Sciences (THS). After promising initial tests, Professor Johnson and his team have received significant funding through the beLAB1407 BRIDGE partnership to further advance the development of this innovative therapeutic.
• In January 2025, Cyclarity Therapeutics is working on a cost-effective small molecule drug aimed at eliminating arterial plaque, thus potentially addressing the globally leading cause of death: cardiovascular disease. Its primary cyclodextrin drug candidate, UDP-003, focuses on 7-ketocholesterol, a type of oxidized cholesterol that increases in cells and tissues as people age. Atherosclerosis occurs when plaque accumulates in the arteries, primarily due to this oxidized cholesterol buildup.
• In November 2024, New microscopic particles – less than a thousandth of a millimetre in size – could hold the key to preventing cardiovascular diseases such as coronary heart disease and ischaemic stroke. Researchers from the NUS Yong Loo Lin School of Medicine (NUS Medicine) have developed a nanoparticle that can diagnose the build-up of plaque in the arteries, otherwise known as atherosclerosis, as well as target atherosclerotic plaques and deliver therapeutic agents. A nanoparticle is a material with a diameter of between one and 100 nanometres, which is one-billionth of a metre.
• In April 2024, a treatment that has shown success in reducing plaque development in mice has now been tested in individuals with psoriasis. Jan Nilsson from Lund University, one of the researchers behind the clinical study, found that the treatment reduced inflammation in the coronary arteries, potentially lowering the risk of heart attack-related death. In the future, individuals with diabetes may also benefit from this treatment. Nilsson, a cardiovascular researcher and Senior Consultant at Skåne University Hospital in Sweden, has encountered many cardiovascular patients who, despite receiving treatment, continue to suffer from heart attacks, strokes, or even death linked to these events.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi S.A.
• AstraZeneca Plc
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc

Report Scope:

In this report, the Global Atherosclerosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Atherosclerosis Drugs Market, By Diagnosis:

o   Ankle-brachial Index

o   Doppler Ultrasound

o   Echocardiogram Electrocardiogram Blood Tests

o   Others

• Atherosclerosis Drugs Market, By Treatment :

o   Medication

o   Surgery

o   Others

• Atherosclerosis Drugs Market, By Route of Administration:

o   Oral

o   Parenteral

o   Others

• Atherosclerosis Drugs Market, By End User:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Atherosclerosis Drugs Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Atherosclerosis Drugs Market.

Available Customizations:

Global Atherosclerosis Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).